

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 June 2016

Cumulative for April, May and June 2016



Contents

Summary of decisions effective 1 June 2016.....	3
Section H changes to Part II	4
Index.....	13

Summary of decisions

EFFECTIVE 1 JUNE 2016

- Aluminium hydroxide with magnesium hydroxide and simethicone (e.g. Mylanta) oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml – to be delisted 1 August 2016
- Apomorphine hydrochloride (Apomine) inj 10 mg per ml, 2 ml ampoule – to be delisted 1 August 2016
- Bismuth trioxide (De-Nol) tab 120 mg – to be delisted 1 January 2017
- Calcitriol (Calcitriol-AFT) cap 0.25 mcg and 0.5 mcg – price decrease and addition of HSS
- Calcitriol (Airflow) cap 0.25 mcg and 0.5 mcg – to be delisted 1 August 2016
- Cetomacrogol with glycerol (Pharmacy Health Sorbolene with Glycerin) crm 90% with glycerol 10%, 500 ml and 1,000 ml – price decrease and addition of HSS
- Cetomacrogol with glycerol (healthE) crm 90% with glycerol 10%, 500 ml, 1 bottle – to be delisted 1 August 2016
- Colloidal bismuth subcitrate (Gastrodenol) tab 120 mg – new listing
- Lisuride hydrogen maleate (Dopergin) tab 200 mcg – to be delisted 1 September 2016
- Metoprolol succinate (Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg, 90 tab pack size – HSS delayed until 1 November 2016
- Metoprolol tartrate (Apo-Metoprolol) tab 50 mg and 100 mg – new listing and addition of HSS
- Metoprolol tartrate (Lopresor) tab 50 mg and 100 mg – to be delisted 1 August 2016
- Olopatadine (Patanol) eye drops 0.1%, 5 ml – new listing
- Oxaliplatin (Oxallicord) inj 5 mg per ml, 10 ml and 20 ml vials – HSS reinstated
- Progesterone (Utrogestan) cap 100 mg – addition of HSS
- Rocuronium bromide (DBL Rocuronium Bromide) inj 10 mg per ml, 5 ml vial – price decrease and addition of HSS
- Siltuximab (Sylvant) inj 100 mg and 400 mg vials – new listing and addition of HSS
- Thymol glycerin (PSM) compound, BPC, 500 ml – new listing and addition of HSS
- Tiotropium bromide soln for inhalation 2.5 mcg per dose (Spiriva Respimat) and powder for inhalation 18 mcg per dose (Spiriva) – amended restriction

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 June 2016

ALIMENTARY TRACT AND METABOLISM

13	ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE (delisting) Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml.....			<i>e.g. Mylanta</i>
	Note – Aluminium hydrochloride with magnesium hydroxide and simethicone oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml to be delisted from 1 August 2016.			
16	COLLOIDAL BISMUTH SUBCITRATE Tab 120 mg	14.51	50	Gastrodenol
16	BISMUTH TRIOXIDE (delisting) Tab 120 mg	32.50	112	De-Nol
	Note – De-Nol tab 120 mg to be delisted from 1 January 2017.			
23	THYMOL GLYCERIN Compound, BPC – 1% DV Aug-16 to 2019	9.15	500 ml	PSM
26	CALCITRIOL (↓ price and addition of HSS) Cap 0.25 mcg – 1% DV Aug-16 to 2019	9.95	100	Calcitriol-AFT
	Cap 0.5 mcg – 1% DV Aug-16 to 2019	18.39	100	Calcitriol-AFT
	Note – Airflow calcitriol cap 0.25 mcg and 0.5 mcg to be delisted from 1 August 2016.			

CARDIOVASCULAR SYSTEM

42	METOPROLOL SUCCINATE (HSS delayed) Tab long-acting 23.75 mg – 1% DV Nov-16 Jun-16 to 2018	2.39	90	Metoprolol - AFT CR
	Tab long-acting 47.5 mg – 1% DV Nov-16 Jun-16 to 2018	3.48	90	Metoprolol - AFT CR
	Tab long-acting 95 mg – 1% DV Nov-16 Jun-16 to 2018	5.73	90	Metoprolol - AFT CR
	Tab long-acting 190 mg – 1% DV Nov-16 Jun-16 to 2018	11.54	90	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg, 30 tablet pack, delisting remains at 1 June 2016.			
42	METOPROLOL TARTRATE Tab 50 mg – 1% DV Aug-16 to 2018	4.64	100	Apo-Metoprolol
	Tab 100 mg – 1% DV Aug-16 to 2018	6.09	60	Apo-Metoprolol
	Note – Lopresor tab 50 mg and 100 mg to be delisted from 1 August 2016.			

DERMATOLOGICALS

53	CETOMACROGOL WITH GLYCEROL (↓ price and addition of HSS) Crm 90% with glycerol 10% – 1% DV Aug-16 to 2019	2.82	500 ml	Pharmacy Health Sorbolene with Glycerin
		3.87	1,000 ml	Pharmacy Health Sorbolene with Glycerin
	Note – healthE crm 90% with glycerol 10%, 500 ml, 1 bottle to be delisted from 1 August 2016.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2016 (continued)

GENITO-URINARY SYSTEM

59	PROGESTERONE (addition of HSS) → Cap 100 mg – 1% DV Aug-16 to 2019.....	16.50	30	Utrogestan
----	--	-------	----	-------------------

MUSCULOSKELETAL SYSTEM

102	ROCURONIUM BROMIDE (↓ price and addition of HSS) Inj 10 mg per ml, 5 ml vial – 1% DV Aug-16 to 2019.....	25.95	10	DBL Rocuronium Bromide
-----	---	-------	----	-----------------------------------

NERVOUS SYSTEM

105	APOMORPHINE HYDROCHLORIDE (delisting) Inj 10 mg per ml, 2 ml ampoule.....	119.00	5	Apomine
Note – Apomine inj 10 mg per ml, 2 ml ampoule to be delisted from 1 August 2016.				
106	LISURIDE HYDROGEN MALEATE (delisting) Tab 200 mcg.....	25.00	30	Dopergin
Note – Dopergin tab 200 mcg to be delisted from 1 September 2016.				

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	OXALIPLATIN (HSS reinstated) Inj 5 mg per ml, 10 ml vial – 1% DV Jun-16 to 2018	13.32	1	Oxaliccord
	Inj 5 mg per ml, 20 ml vial – 1% DV Jun-16 to 2018	16.00	1	Oxaliccord

151	SILTUXIMAB → Inj 100 mg vial – 1% DV Jun-16 to 2018	770.57	1	Sylvant
	→ Inj 400 mg vial – 1% DV Jun-16 to 2018	3,082.33	1	Sylvant

Restricted

Initiation

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

1. Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
2. Treatment with an adequate trial of corticosteroids has proven ineffective; and
3. Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 June 2016 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

178	TIOTROPIUM BROMIDE (amended restriction) Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.			
	→ Soln for inhalation 2.5 mcg per dose	70.00	60 dose	Spiriva Respimat
	→ Powder for inhalation 18 mcg per dose	70.00	30 dose	Spiriva
	Restricted Initiation All of the following:			
	1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and			
	2 In addition to standard treatment, the patient has trialed a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and			
	3 Either: the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:			
	3.1 Grade 3 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or			
	3.2 Grade 4 5 (too breathless to leave the house, or breathless when dressing or undressing); and			
	4 Actual FEV ₁ as a % of predicted, must be below 60%; and			
	5 Either:			
	5.1 Patient is not a smoker (for reporting purposes only); or			
	5.2 Patient is a smoker and has been offered smoking cessation counselling; and			
	6 The patient has been offered annual influenza immunization.			

SENSORY ORGANS

184	OLOPATADINE Eye drops 0.1%	17.00	5 ml	Patanol
-----	-------------------------------------	-------	------	---------

Effective 1 May 2016

ALIMENTARY TRACT AND METABOLISM

20	GALSULFASE → Inj 1 mg per ml, 5 ml vial – 1% DV May-16 to 2018	2,234.00	1	Naglazyme
	Restricted Initiation Metabolic physician <i>Re-assessment required after 12 months</i> Both:			
	1 The patient has diagnosis of mucopolysaccharidosis VI; and			
	2 Either:			
	2.1 Diagnosis confirmed by demonstration of N-acetyl galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either an enzyme activity assay in leukocytes or skin fibroblasts; or			
	2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.			
	Continuation Metabolic physician <i>Re-assessment required after 12 months</i> All of the following:			

continued...

→ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

continued...

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

CARDIOVASCULAR SYSTEM

40	PHENTOLAMINE MESYLATE (new presentation) Inj 5 mg per ml, 1 ml ampoule			
42	METOPROLOL SUCCINATE (↓ price)			
	Tab long-acting 23.75 mg	0.80	30	Metoprolol - AFT CR
	Tab long-acting 47.5 mg	1.16	30	Metoprolol - AFT CR
	Tab long-acting 95 mg	1.91	30	Metoprolol - AFT CR
	Tab long-acting 190 mg	3.85	30	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting, all strengths of the 30 tab pack size, to be delisted from 1 June 2016.			
48	MILRINONE (new listing and addition of HSS) Inj 1 mg per ml, 10 ml ampoule – 1% DV Jul-16 to 2018	300.30	10	Milrinone Generic Health

GENITO-URINARY SYSTEM

57	INTRA-UTERINE DEVICE (new listing) IUD 35.5 mm length × 19.6 mm width	31.60	1	Choice Load 375
----	--	-------	---	-----------------

HORMONE PREPARATIONS

61	CINACALCET (new listing) → Tab 30 mg	403.70	28	Sensipar
	Restricted			
	Initiation			
	Nephrologist or endocrinologist			
	<i>Re-assessment required after 6 months</i>			
	Either:			
	1 All of the following:			
	1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and			
	1.2 The patient has persistent hypercalcaemia (serum calcium ≥3 mmol/L) despite previous first-line treatments including bisphosphonates and sodium thiosulfate; and			
	1.3 The patient is symptomatic; or			
	2 All of the following:			
	2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriopathy); and			
	2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium ≥3 mmol/L); and			
	2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.			
	Continuation			
	Nephrologist or endocrinologist			

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

continued...

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.

Note: this does not include parathyroid adenomas unless these have become malignant.

INFECTIONS

71	GENTAMICIN SULPHATE (additional pack size) Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	30.00	50	Pfizer
74	AMOXICILLIN WITH CLAVULANIC ACID (addition of HSS) Tab 500 mg with clavulanic acid 125 mg – 1% DV Aug-16 to 2017	1.95	20	Augmentin
Note – Curam Duo tab 500 mg with clavulanic acid 125 mg to be delisted from 1 August 2016.				
93	PEGYLATED INTERFERON ALFA-2A (delisting) Inj 135 mcg prefilled syringe Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) Note – Pegylated interferon alfa-2a inj 135 mcg prefilled syringe, and inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) to be delisted from 1 July 2016			

NERVOUS SYSTEM

105	APOMORPHINE HYDROCHLORIDE (new listing) Inj 10 mg per ml, 2 ml ampoule	119.00	5	Movapo
124	BUSPIRONE HYDROCHLORIDE (new listing and addition of HSS) Tab 5 mg – 1% DV Jul-16 to 2018	23.80	100	Orion
	Tab 10 mg – 1% DV Jul-16 to 2018	14.96	100	Orion
Note – Pacific Buspirone tab 5 mg and 10 mg to be delisted from 1 July 2016.				

SENSORY ORGANS

183	CHLORAMPHENICOL (↓ price and addition of HSS) Eye oint 1% – 1% DV Jul-16 to 2019	2.48	4 g	Chlorsig
187	BIMATOPROST (new listing and addition of HSS) Eye drops 0.03% – 1% DV Jul-16 to 2018	3.65	3 ml	Bimatoprost Actavis

VARIOUS

190	DIMERCAPTOSUCCINIC ACID (addition of example brand) Cap 100 mg			<i>e.g. Pharmaceutical Compounding NZ</i>
190	DIMERCAPTOSUCCINIC ACID (new presentation) Cap 200 mg			<i>e.g. Pharmaceutical Compounding NZ</i>

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

191	ISOPROPYL ALCOHOL (delisting)			
	Soln 70%, 500 ml.....	5.00	1	PSM
		60.00	12	PSM

Note – PSM isopropyl alcohol soln 70%, 500 ml, 1 bottle and 12 bottle packs, to be delisted from 1 July 2016.

SPECIAL FOODS

206	FAT-MODIFIED FEED (new listing)			
	Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
210	HIGH FAT FORMULA (amended presentation description)			
	Powder 14.4 g 15.25 g protein, 2.9 g 3 g carbohydrate and 69.2 g 73 g fat per 100 g, can.....	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)

Effective 1 April 2016

ALIMENTARY TRACT AND METABOLISM

15	MISOPROSTOL (new listing and addition of HSS)			
	Tab 200 mcg – 1% DV Jun-16 to 2019	41.50	120	Cytotec
16	OMEPRAZOLE (↑ price)			
	Inj 40 mg ampoule with diluent	33.65	5	Dr Reddy's Omeprazole

CARDIOVASCULAR SYSTEM

41	DIGOXIN (new listing and addition of HSS)			
	Tab 62.5 mcg – 1% DV Jun-16 to 2019	6.67	240	Lanoxin PG
	Tab 250 mcg – 1% DV Jun-16 to 2019	14.52	240	Lanoxin
42	METOPROLOL SUCCINATE			
	Tab long-acting 190 mg – 1% DV Jun-16 to 2018	11.54	90	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting 190 mg, 30 tab pack, to be delisted from 1 June 2016.			
44	FUROSEMIDE [FRUSEMIDE] (↑ price and addition of HSS)			
	Inj 10 mg per ml, 2 ml ampoule – 1% DV Jun-16 to 2019	1.20	5	Frusemide-Claris
44	PERHEXILINE MALEATE (addition of HSS)			
	Tab 100 mg – 1% DV Jun-16 to 2019	62.90	100	Pexsig
47	ISOSORBIDE MONONITRATE (addition of HSS)			
	Tab long-acting 40 mg – 1% DV Jun-16 to 2019	7.50	30	Ismo 40 Retard

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

GENITO-URINARY SYSTEM

59	DINOPROSTONE (amended presentation description)			
	Vaginal gel 1 mg in 3 g 2.5 ml	52.65	1	Prostin E2
	Vaginal gel 2 mg in 3 g 2.5 ml	64.60	1	Prostin E2

HORMONE PREPARATIONS

69	DESMOPRESSIN ACETATE (↓ price and addition of HSS)			
	→ Tab 100 mcg – 1% DV Jun-16 to 2019	25.00	30	Minirin
	→ Tab 200 mcg – 1% DV Jun-16 to 2019	54.45	30	Minirin

INFECTIONS

73	CLARITHROMYCIN			
	→ Grans for oral liq 50 mg per ml	23.12	50 ml	Klacid
	Note – Klacid grans for oral liq 25 mg per ml, 70 ml to be delisted from 1 October 2016.			

MUSCULOSKELETAL SYSTEM

95	LEFLUNOMIDE (delisting)			
	Tab 100 mg	54.44	3	Arava
	Note – Arava tab 100 mg to be delisted from 1 April 2016.			
102	CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
	Inj 300 u vial	388.50	1	Dysport

NERVOUS SYSTEM

107	PROPOFOL (↓ price addition of HSS)			
	Inj 10 mg per ml, 20 ml vial – 10% DV Jun-16 to 2019	5.27	5	Provive MCT-LCT 1%
107	PROPOFOL (new listing)			
	Inj 10 mg per ml, 50 ml vial – 10% DV Jun-16 to 2019	24.50	10	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 100 ml vial – 10% DV Jun-16 to 2019	49.00	10	Fresofol 1% MCT/LCT
107	PROPOFOL (delisting)			
	Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
	Inj 10 mg per ml, 20 ml vial	42.00	5	Diprivan
	Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
	Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
		25.00		Provive MCT-LCT 1%
				Diprivan
	Inj 10 mg per ml, 100 ml vial	7.60	1	Fresofol 1%
				Provive MCT-LCT 1%

Note – Fresofol 1% inj 10 mg per ml, 20 ml ampoule, 50 ml vial and 100 ml vial to be delisted from 1 June 2016.
 Note – Diprivan inj 10 mg per ml, 20 ml vial, 50 ml syringe, and 50 ml vial to be delisted from 1 June 2016.
 Note – Provive MCT-LCT 1% inj 10 mg per ml, 50 ml vial, 1 inj pack size and 100 ml vial, 1 inj pack size, to be delisted from 1 June 2016.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

108	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag		
123	FLUPHENAZINE DECANOATE Inj 25 mg per ml, 2 ml ampoule		<i>e.g. Modecate</i>

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	OXALIPLATIN (HSS suspended) Inj 5 mg per ml, 10 ml vial		
	– 1% DV Mar-16 to 2018 31/3/16	13.32	1 Oxaliccord
	Inj 5 mg per ml, 20 ml vial		
	– 1% DV Mar-16 to 2018 31/3/16	16.00	1 Oxaliccord

Note – HSS for Oxaliccord inj 5 mg per ml, 10 ml and 20 ml vials has been suspended and will be reinstated from 1 June 2016 until 30 June 2018.

RESPIRATORY SYSTEM AND ALLERGIES

176	BEE VENOM (new listing) → Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent		
176	PAPER WASP VENOM (new listing) → Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent		
176	YELLOW JACKET WASP VENOM (new listing) → Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent		

SENSORY ORGANS

188	POLYVINYL ALCOHOL (↓ price and addition of HSS)		
	Eye drops 1.4% – 1% DV Jun-16 to 2019	2.62	15 ml Vistil
	Eye drops 3% – 1% DV Jun-16 to 2019	3.68	15 ml Vistil Forte

Note – Liquifilm Tears eye drops 1.4% and Liquifilm Forte eye drops 3% to be delisted from 1 June 2016.

VARIOUS

192	IODISED OIL (↑ price) Inj 38% w/w (480 mg per ml), 10 ml ampoule	191.00	1 Lipiodol Ultra Fluid
-----	---	--------	------------------------

SPECIAL FOODS

205	AMINO ACID ORAL FEED (new listing) → Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet	4.50	80 g Vivonex TEN
205	AMINO ACID ORAL FEED (delisting) → Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet	4.50	80.4 g Vivonex TEN

Note – Vivonex TEN powder, 80.4 g pack size, to be delisted from 1 June 2016.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

213	ENTERAL FEED 1 KCAL/ML			
	→ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	2.65	500 ml	Osmolite RTH
	→ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can	1.24	250 ml	Osmolite
	Note – Osmolite RTH 500 ml and Osmolite 250 ml to be delisted from 1 June 2016.			

Index

Pharmaceuticals and brands

A		
Aluminium hydroxide with magnesium hydroxide and simethicone.....	4	
Amino acid oral feed	11	
Amoxicillin with clavulanic acid	8	
Apo-Metoprolol	4	
Apomine	5	
Apomorphine hydrochloride	5, 8	
Arava	10	
Augmentin	8	
B		
Bee venom.....	11	
Bimatoprost	8	
Bimatoprost Actavis	8	
Bismuth trioxide	4	
Bupivacaine hydrochloride with fentanyl	11	
Buspirone hydrochloride.....	8	
C		
Calcitriol	4	
Calcitriol-AFT	4	
Cetomacrogol with glycerol	4	
Chloramphenicol	8	
Chlorsig	8	
Choice Load 375.....	7	
Cinacalcet.....	7	
Clarithromycin.....	10	
Clostridium botulinum type a toxin.....	10	
Colloidal bismuth subcitrate	4	
Cytotec	9	
D		
DBL Rocuronium Bromide.....	5	
De-Nol	4	
Desmopressin acetate.....	10	
Digoxin	9	
Dimercaptosuccinic acid	8	
Dinoprostone	10	
Diprivan	10	
Dopergin.....	5	
Dr Reddy's Omeprazole.....	9	
Dysport.....	10	
E		
Enteral feed 1 kcal/ml.....	12	
F		
Fat-modified feed	9	
Fluphenazine decanoate	11	
Fresofol 1%.....	10	
Fresofol 1% MCT/LCT	10	
Frusemide.....	9	
Frusemide-Claris	9	
Furosemide	9	
G		
Galsulfase.....	6	
Gastrodenol	4	
Gentamicin sulphate.....	8	
H		
High fat formula	9	
I		
Intra-uterine device.....	7	
Iodised oil	11	
Ismo 40 Retard	9	
Isopropyl alcohol.....	9	
Isosorbide mononitrate.....	9	
K		
Ketocal 4:1 (Unflavoured).....	9	
Ketocal 4:1 (Vanilla).....	9	
Klacid	10	
L		
Lanoxin.....	9	
Lanoxin PG	9	
Leflunomide.....	10	
Lipiodol Ultra Fluid	11	
Lisuride hydrogen maleate.....	5	
M		
Metoprolol - AFT CR.....	4, 7, 9	
Metoprolol succinate.....	4, 7, 9	
Metoprolol tartrate.....	4	
Milrinone.....	7	
Milrinone Generic Health.....	7	
Minirin	10	
Misoprostol.....	9	
Modecate.....	11	
Movapo	8	
N		
Naglazyme	6	
O		
Olopatadine.....	6	
Omeprazole.....	9	
Osmolite	12	
Osmolite RTH.....	12	
Oxallicord.....	5, 11	
Oxaliplatin	5, 11	
P		
Paper wasp venom	11	
Patanol	6	
Pegylated interferon alfa-2a	8	
Perhexiline maleate	9	
Pexsig.....	9	
Pharmacy Health Sorbolene with Glycerin.....	4	
Phentolamine mesylate	7	
Polyvinyl alcohol	11	
Progesterone	5	

Index

Pharmaceuticals and brands

Propofol.....	10	T	
Prostin E2.....	10	Thymol glycerin	4
Provive MCT-LCT 1%	10	Tiotropium bromide.....	6
R		U	
Rocuronium bromide	5	Utrogestan	5
S		V	
Sensipar	7	Vistil	11
Siltuximab.....	5	Vistil Forte.....	11
Spiriva	6	Vivonex TEN.....	11
Spiriva Respimat.....	6	Y	
Sylvant	5	Yellow jacket wasp venom	11



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand